ClinicalTrials.gg
Not yet recruitingNCT07658339Updated Jun 22, 2026

A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of HSK39004 Inhalation Suspension in Patients With COPD

A Phase 3 interventional study of HSK39004 Inhalation Suspension and Placebo control in COPD (Chronic Obstructive Pulmonary Disease), sponsored by Haisco Pharmaceutical Group Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
387
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Pulmonary Disease, Chronic Obstructive by Haisco Pharmaceutical Group Co., Ltd. — 6 open to participants now, 8 under way, 3 of them phase 3. Pulmonary Disease, Chronic Obstructive · Haisco Pharmaceutical Group Co., Ltd..

Planned enrollment
2nd of 10
387 · median 300
Started
2026
with 3 others
Phase 3
4 of 10
3 open now
Registered
9th of 10
by date

Among the 10 studies in Pulmonary Disease, Chronic Obstructive by Haisco Pharmaceutical Group Co., Ltd., this one is the 2nd largest by planned enrollment, is one of 4 that started in 2026, is one of 4 in phase 3, and was the 9th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

6 of the 10 studies in Pulmonary Disease, Chronic Obstructive by Haisco Pharmaceutical Group Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Pulmonary Disease, Chronic Obstructive by Haisco Pharmaceutical Group Co., Ltd., or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of HSK39004 Inhalation Suspension in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).

03

Conditions studied

  • COPD (Chronic Obstructive Pulmonary Disease)

Keywords

  • PDE3/4
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Aged 40 to 80 years (inclusive) at the time of screening visit (Visit 1), male or female;
  2. Subjects diagnosed with (COPD) in accordance with the GOLD 2026 diagnostic criteria prior to screening [GOLD 2026 criteria: presence of chronic respiratory symptoms such as dyspnea, chronic cough or sputum production, and/or a history of risk factor exposure, and the pulmonary function test results show: the (FEV1) after using bronchodilators / forced vital capacity (FVC) \<0.7];
  3. At screening visit (Visit 1):

    • Post-bronchodilator FEV1/FVC \< 0.7; and
    • Post-bronchodilator FEV1 ≥ 30% and \< 80% of predicted value;
  4. Modified Medical Research Council (mMRC) dyspnea scale score ≥ 2 at screening;

Key Exclusion Criteria:

  1. Known to HSK39004 inhalation suspension, salbutamol, or any component of the drug delivery system;
  2. History of life-threatening acute exacerbation of COPD;
  3. Acute exacerbation of COPD (excluding the use of short-acting bronchodilators alone) or hospitalization for pneumonia within 12 weeks prior to screening (Visit 1);
  4. Acute (viral or bacterial) upper or lower respiratory tract infection within 6 weeks prior to screening (Visit 1);
  5. Diagnosis of any other respiratory disease besides COPD, including but not limited to: alpha-1 antitrypsin deficiency, bronchial asthma, active tuberculosis, lung cancer, pulmonary edema, cystic fibrosis, bronchiolitis obliterans, pulmonary sarcoidosis, or clinically significant idiopathic pulmonary fibrosis, pulmonary arterial hypertension, bronchiectasis (except asymptomatic localized bronchiectasis) that, in the opinion of the investigator, poses a safety risk to the participant or may affect the analysis of study result;
  6. Severe or uncontrolled cardiovascular disease or history;
  7. History of (except for carcinoma in situ, cutaneous squamous cell carcinoma, and basal cell carcinoma cured for more than 5 years), suspected malignancy, or undetermined neoplasm;
  8. Concurrent severe, uncontrolled renal, neurological, endocrine, thyroid, urological, ophthalmic, immunological, psychiatric, gastrointestinal, hepatic, or hematological diseases/abnormalities that, in the investigator's judgment, may pose a safety risk to the subject or confound study outcome analysis;
  9. History of lung lobectomy or lung volume reduction surgery within 12 months prior to screening;
  10. Subjects determined by the investigator to require oxygen therapy;
  11. Clinically significant sleep apnea requiring continuous positive airway pressure (CPAP) or non-invasive positive pressure ventilation (NIPPV)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
387 participants (estimated)

Study arms

  • Experimental
    HSK39004 Inhalation Suspension

    3 mg BID

    Drug: HSK39004 Inhalation Suspension

  • Placebo comparator
    Placebo control

    BID

    Drug: Placebo control

Interventions

  • Dosage Formulation: HSK39004 Inhalation suspension Dosage 3mg,Twice Daily for 24 weeks

  • DrugPlacebo control

    Dosage Formulation: Placebo Inhalation suspension Dosage 0mg,Twice Daily for 24 weeks

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Average Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12h) at Week 12

    Average FEV1 AUC0-12h was defined as AUC over 12 hours of the FEV1, divided by 12 hours. Baseline FEV1 is the mean of the 2 measurements taken before study medication on the day of first dosing.

    Time frame: Baseline (pre-dose on Day 1) and Week 12

Secondary outcomes

  1. Change from Baseline in peak FEV1 within 4 hours after administration at week 4, 8, 12, 18, 24

    Peak FEV1 is the maximum value in the 4 hours after dosing. Baseline FEV1 is the mean of the 2 measurements taken before study medication on the day of first dosing.

    Time frame: Baseline (pre-dose on Day 1) and Week 4, 8, 12, 18, 24

  2. Change from Baseline in Morning trough FEV1 after administration at week 4, 8, 12, 18, 24

    Morning trough FEV1 was the last value collected prior to the morning dose. Baseline FEV1 is the mean of the 2 measurements taken before study medication on the day of first dosing.

    Time frame: Baseline (pre-dose on Day 1) and week 4, 8, 12, 18, 24

  3. Change from Baseline in Average Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-4h) at Week 4, 8, 12, 18, 24

    Average FEV1 AUC0-4h was defined as AUC over 4 hours of the FEV1, divided by 4 hours. Baseline FEV1 is the mean of the 2 measurements taken before study medication on the day of first dosing.

    Time frame: Baseline (pre-dose on Day 1) and Week 4, 8, 12, 18, 24

  4. Change From Baseline in the St. George's Respiratory Questionnaire (SGRQ) Total Score at Weeks 12 and 24

    The SGRQ questionnaire consists of 17 questions, split into 2 parts. Part 1 consisted of the first 8 questions and was related to the symptoms subdomain. The remaining 9 questions were in Part 2, which were related to the activity and impacts subdomains. The total score was calculated by dividing the summed weights by the maximum possible weight for all items in the questionnaire and expressing the result as a percentage. Score ranging from 0 to 100 and higher scores indicated a worse outcome. Baseline is the score calculated on Day 1.

    Time frame: Day1, Weeks 12 and 24

  5. Treatment-emergent adverse event (TEAE) incidence

    The incidence of treatment-emergent adverse events (TEAEs), assessed through vital signs, physical examinations, laboratory tests, 12-lead ECG parameters, and detailed adverse event monitoring.

    Time frame: From week 1 to week 25

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Jun 2027, 11 months later.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's planned 11 months is below that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2026
First posted
Jun 22, 2026
StartEst.
Jul 11, 2026
Primary completionEst.
Jun 11, 2027
CompletionEst.
Jun 11, 2027
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07658339
Responsible party
Sponsor
First posted
Jun 22, 2026
Start date
Jul 11, 2026 (estimated)
Primary completion
Jun 11, 2027 (estimated)
Completion
Jun 11, 2027 (estimated)
Last update
Jun 22, 2026

Study contacts

Yongchang Sun, Doctor
Contact
suny@bjmu.edu.cn
(+86)13910979132

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HSK39004

Start the discussion